Sionna Therapeutics (NASDAQ:SION) Upgraded to "Strong-Buy" at Wedbush

Key Points

• Wedbush upgraded Sionna Therapeutics (NASDAQ:SION) to a "strong‑buy" and multiple firms have issued buy/strong‑buy ratings, with the stock's consensus labeled "Moderate Buy" and an average target price of $53.
• SION opened at $40.97 (12‑month range $11.77–$46.46) with a market cap of about $1.85 billion; the company beat Q results (EPS -$0.46 vs. -$0.61 expected) but remains unprofitable and is forecast to post roughly -2.44 EPS for the year.
• Insiders sold heavily last quarter—1,131,856 shares valued at ~$50.8 million (including director sales executed under Rule 10b5‑1)—with insiders still owning about 3.90% of the company.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) was upgraded by analysts at Wedbush to a "strong-buy" rating in a research report issued to clients and investors on Monday,Zacks.com reports.

Several other equities analysts have also weighed in on the company. Raymond James Financial reaffirmed a "strong-buy" rating and issued a $53.00 price objective on shares of Sionna Therapeutics in a research note on Monday, January 5th. Citizens Jmp started coverage on shares of Sionna Therapeutics in a report on Tuesday, February 24th. They issued a "market outperform" rating and a $63.00 price target on the stock. BTIG Research reaffirmed a "buy" rating and set a $58.00 price target on shares of Sionna Therapeutics in a research report on Monday, April 27th. JonesTrading boosted their price objective on shares of Sionna Therapeutics from $52.00 to $63.00 and gave the stock a "buy" rating in a research note on Tuesday, April 28th. Finally, Citigroup initiated coverage on shares of Sionna Therapeutics in a research report on Tuesday, February 24th. They issued an "outperform" rating for the company. Three research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $53.00.

Sionna Therapeutics Trading Up 1.3%

Shares of SION opened at $40.97 on Monday. Sionna Therapeutics has a twelve month low of $11.77 and a twelve month high of $46.46. The firm has a market capitalization of $1.85 billion, a P/E ratio of -21.01 and a beta of 1.35. The stock's fifty day simple moving average is $38.29 and its 200 day simple moving average is $39.20.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last posted its quarterly earnings results on Monday, March 2nd. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.61) by $0.15. Sell-side analysts predict that Sionna Therapeutics will post -2.44 earnings per share for the current year.

Insider Transactions at Sionna Therapeutics

In other news, Director Peter A. Thompson sold 2,948 shares of the stock in a transaction dated Saturday, April 18th. The stock was sold at an average price of $44.52, for a total value of $131,244.96. Following the completion of the sale, the director owned 2,964,774 shares in the company, valued at approximately $131,991,738.48. This trade represents a 0.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 2,948 shares of the firm's stock in a transaction dated Saturday, April 18th. The shares were sold at an average price of $44.52, for a total value of $131,244.96. Following the sale, the director owned 2,964,774 shares in the company, valued at approximately $131,991,738.48. The trade was a 0.10% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 1,131,856 shares of company stock valued at $50,834,773. Insiders own 3.90% of the company's stock.

Institutional Trading of Sionna Therapeutics

A number of hedge funds have recently made changes to their positions in SION. Deutsche Bank AG boosted its stake in shares of Sionna Therapeutics by 4.5% in the fourth quarter. Deutsche Bank AG now owns 10,029 shares of the company's stock valued at $413,000 after purchasing an additional 433 shares during the period. Bank of America Corp DE increased its stake in Sionna Therapeutics by 8.8% during the 3rd quarter. Bank of America Corp DE now owns 6,541 shares of the company's stock worth $192,000 after buying an additional 529 shares during the period. MetLife Investment Management LLC increased its stake in Sionna Therapeutics by 6.6% during the 4th quarter. MetLife Investment Management LLC now owns 8,565 shares of the company's stock worth $352,000 after buying an additional 532 shares during the period. BNP Paribas Financial Markets lifted its holdings in Sionna Therapeutics by 35.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company's stock worth $70,000 after buying an additional 619 shares in the last quarter. Finally, GF Fund Management CO. LTD. purchased a new position in Sionna Therapeutics in the 4th quarter valued at about $36,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.